361 related articles for article (PubMed ID: 10384102)
1. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
4. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
5. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
[TBL] [Abstract][Full Text] [Related]
7. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation.
Krasteva M; Kehren J; Horand F; Akiba H; Choquet G; Ducluzeau MT; Tédone R; Garrigue JL; Kaiserlian D; Nicolas JF
J Immunol; 1998 Feb; 160(3):1181-90. PubMed ID: 9570532
[TBL] [Abstract][Full Text] [Related]
8. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
9. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
10. Limited costimulatory molecule expression on renal tubular epithelial cells impairs T cell activation.
Waeckerle-Men Y; Starke A; Wahl PR; Wüthrich RP
Kidney Blood Press Res; 2007; 30(6):421-9. PubMed ID: 17975322
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF.
Daro E; Butz E; Smith J; Teepe M; Maliszewski CR; McKenna HJ
Cytokine; 2002 Feb; 17(3):119-30. PubMed ID: 11895330
[TBL] [Abstract][Full Text] [Related]
14. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
[TBL] [Abstract][Full Text] [Related]
15. MHC class II and CD40 play opposing roles in dendritic cell survival.
McLellan A; Heldmann M; Terbeck G; Weih F; Linden C; Bröcker EB; Leverkus M; Kämpgen E
Eur J Immunol; 2000 Sep; 30(9):2612-9. PubMed ID: 11009095
[TBL] [Abstract][Full Text] [Related]
16. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
17. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
19. Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand.
Rizzitelli A; Vremec D; Villadangos JA; Mavaddat N; Wright MD; Shortman K
Eur J Immunol; 2005 Nov; 35(11):3209-20. PubMed ID: 16224811
[TBL] [Abstract][Full Text] [Related]
20. CD40 is necessary for activation of naïve T cells by a dendritic cell line in vivo but not in vitro.
Haase C; Michelsen BK; Jørgensen TN
Scand J Immunol; 2004 Mar; 59(3):237-45. PubMed ID: 15030573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]